June 8, 2023
On June 8, 2023, Antisense Therapeutics announced that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy and the first participant has been randomized and dosed with ATL1102 or Placebo in Turkey.
To read their full press release, please click here.
To learn more about ATL1102, click here.
Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org
Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)Â
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
